Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
pneumococcal vaccine
Biotech
GSK axes vaccine from $2.1B deal, switches to preclinical heir
GSK has axed a pneumococcal 24-valent vaccine for adults from its $2.1 billion Affinivax takeover in favor of a preclinical 30-plus valent shot.
Nick Paul Taylor
Oct 30, 2024 7:06am
Vaxcyte surges on 'stunning' 31-valent PCV win against Pfizer
Sep 3, 2024 10:32am
Merck compares pneumococcal vaccine to 1983 warhorse
Apr 29, 2024 9:00am
GSK tips 12 blockbuster launches to soften HIV patent loss
Jan 31, 2024 7:45am
Merck strides onto Pfizer’s turf with pivotal vaccine data
Nov 28, 2023 8:20am
Pfizer axes RSV, eczema, sickle cell and cancer drugs in cull
Aug 1, 2023 9:00am
